이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

iX Biopharma 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Eddy Lee

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	16.8yrs
CEO 소유권	22.3%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO

Eddy Lee (70 yo)

16.8yrs

테뉴어

Mr. Yip Hang Lee, also known as Eddy, serves as the Chief Executive Officer of iX Biopharma Ltd. and has been its Executive Chairman since January 17, 2008. Mr. Lee is responsible for running the affairs o...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chin Beng Lim	Chief Pharmacist	3.8yrs	데이터 없음	데이터 없음
Yip Hang Lee	Executive Chairman & CEO	no data	데이터 없음	22.25% SGD 5.1m
Sien Lup Chew	Chief Financial Officer	8.5yrs	데이터 없음	데이터 없음
Janakan Krishnarajah	COO & Chief Medical Officer	5.5yrs	데이터 없음	데이터 없음
Iain Cook	Chief Scientist	9.1yrs	데이터 없음	데이터 없음
Eva Tan	Chief Commercial Officer	3.8yrs	데이터 없음	데이터 없음
Kuan Loong Lai	Secretary	2.7yrs	데이터 없음	데이터 없음
Soo Fern Lee	Secretary	2.7yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 관리: 42C 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yip Hang Lee	Executive Chairman & CEO	16.8yrs	데이터 없음	22.25% SGD 5.1m
Patrick Donald Davies	Non-Executive Lead Independent Director	4.8yrs	데이터 없음	데이터 없음
Shing Tung Ho	Non-Executive Non-Independent Director	11.6yrs	데이터 없음	1.03% SGD 237.3k
Bob Rappaport	Member of Scientific Advisory Board	8.5yrs	데이터 없음	데이터 없음
Stephan A. Schug	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Vivian Sunderland	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yandi Liu	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Xiwen Tham	Independent Non-Executive Director	2.7yrs	데이터 없음	데이터 없음
Woon Keng Teo	Independent Non-Executive Director	1.9yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

경험이 풍부한 이사회: 42C 의 이사회는 경험(평균 재직 기간 4.7 년)으로 간주됩니다.

iX Biopharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024

iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023

iX Biopharma Ltd. Announces Board and Committee Appointment

iX Biopharma Ltd., Annual General Meeting, Oct 14, 2022

iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd

iX Biopharma Ltd. Announces Executive Changes

Recent updates

Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023)

iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024

Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023)

New minor risk - Financial data availability

New minor risk - Shareholder dilution

New major risk - Financial position

iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023

Full year 2023 earnings released: S$0.013 loss per share (vs S$0.006 loss in FY 2022)

New major risk - Share price stability

New minor risk - Financial data availability

iX Biopharma Ltd. announced that it has received SGD 2 million in funding

iX Biopharma Ltd. announced that it expects to receive SGD 2 million in funding

First half 2023 earnings released: S$0.01 loss per share (vs S$0.005 profit in 1H 2022)

iX Biopharma Ltd Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study

Forecast to breakeven in 2024

iX Biopharma Ltd. Announces Board and Committee Appointment

iX Biopharma Ltd., Annual General Meeting, Oct 14, 2022

Full year 2022 earnings released: S$0.006 loss per share (vs S$0.012 loss in FY 2021)

iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 2.742 million.

iX Biopharma Ltd. Announces Drug Development Updates for Wafermine and Wafesil

iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd

Price target decreased to S$0.34

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iX Biopharma Ltd. Announces Executive Changes

iX Biopharma Ltd Appoints Angeline Tham as Non-Executive Independent Director, Member of Audit Committee and Remuneration Committee and Chairperson of Nominating Committee, Effective 1 February 2022

No longer forecast to breakeven

Price target decreased to S$0.34

Full year 2021 earnings released: S$0.012 loss per share (vs S$0.016 loss in FY 2020)

Full year 2021 earnings released: S$0.008 loss per share (vs S$0.016 loss in FY 2020)

Executive Chairman & CEO exercised options to buy S$2.7m worth of stock.

iX Biopharma Ltd to Participate in Study with Wafermine for Treatment of Breakthrough Pain in Advanced Cancer Patients

iX Biopharma Ltd. Appoints Yee Chia Hsing as Director of Corporate Affairs

First half 2021 earnings released: S$0.004 loss per share (vs S$0.009 loss in 1H 2020)

iX Biopharma Ltd. Appoints Ms. Eva Tan as Its New Chief Commercial Officer

Full year earnings released - S$0.016 loss per share

New 90-day low - S$0.23

iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 10.232999 million.

Full year earnings released

New 90-day high - S$0.34

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간